These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 35909512

  • 1. PEGylated Recombinant Human Growth Hormone Jintrolong® Exhibits Good Long-Term Safety in Cynomolgus Monkeys and Human Pediatric Growth Hormone Deficiency Patients.
    Wu W, Zhou J, Wu C, Zhou Q, Li X, Zhang Y, Zuo C, Yin J, Hou L, Wang S, Gao H, Luo T, Jin L, Zhong E, Wang Y, Luo X.
    Front Endocrinol (Lausanne); 2022; 13():821588. PubMed ID: 35909512
    [Abstract] [Full Text] [Related]

  • 2. Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies.
    Luo X, Hou L, Liang L, Dong G, Shen S, Zhao Z, Gong CX, Li Y, Du ML, Su Z, Du H, Yan C.
    Eur J Endocrinol; 2017 Aug; 177(2):195-205. PubMed ID: 28566441
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A long-acting pegylated recombinant human growth hormone (Jintrolong® ) in healthy adult subjects: Two single-dose trials evaluating safety, tolerability and pharmacokinetics.
    Guan Y, He F, Wu J, Zhao L, Wang X, Huang L, Zeng G, Ren B, Chen J, Liao X, Ma Z, Chen X, Zhong G, Huang M, Zhao X.
    J Clin Pharm Ther; 2018 Oct; 43(5):640-646. PubMed ID: 29959799
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial.
    Sun C, Lu B, Liu Y, Zhang Y, Wei H, Hu X, Hu P, Zhao Q, Liu Y, Ye K, Wang K, Gu Z, Liu Z, Ye J, Zhang H, Zhu H, Jiang Z, Liu Y, Wan N, Yan C, Yin J, Ying L, Huang F, Yin Q, Xi L, Luo F, Cheng R.
    Front Endocrinol (Lausanne); 2021 Oct; 12():779365. PubMed ID: 34899612
    [Abstract] [Full Text] [Related]

  • 7. Long-term Pegylated GH for Children With GH Deficiency: A Large, Prospective, Real-world Study.
    Hou L, Huang K, Gong C, Luo F, Wei H, Liang L, Du H, Zhang J, Zhong Y, Chen R, Chen X, Pan J, Jin X, Zeng T, Liao W, Liu D, Lan D, Zhu S, Dong Z, Ma H, Yang Y, Xiong F, Lu P, Cheng S, Gu X, Jin R, Liu Y, Wu J, Xu X, Chen L, Dong Q, Pan H, Su Z, Liu L, Luo X, Ni S, Chen Z, Hu Y, Wang C, Liu J, Liu L, Lu B, Wang X, Wang Y, Yang F, Zhang M, Cao L, Liu G, Yao H, Zhan Y, Dai M, Li G, Li L, Liu Y, Wang K, Xiao Y, Zhang X, Dong J, Gu Z, Ying L, Huang F, Liu Y, Liu Z, Ye J, Zhao D, Hu X, Jiang Z, Ye K, Zhu H, Chen S, Chen X, Wan N, Xu Z, Yin Q, Zhang H, Huang X, Yin J, Zhang H, Li P, Yin P, Fu J, Luo X.
    J Clin Endocrinol Metab; 2023 Jul 14; 108(8):2078-2086. PubMed ID: 36669772
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Long-term efficacy and safety of PEGylated recombinant human growth hormone in treating Chinese children with growth hormone deficiency: a 5-year retrospective study.
    Hou L, Lin S, Liu Z, Zhang L, Ou H, Huang S, Dai H, Meng Z, Liang L.
    J Pediatr Endocrinol Metab; 2024 Oct 28; 37(10):892-899. PubMed ID: 39190198
    [Abstract] [Full Text] [Related]

  • 11. Adverse vacuolation in multiple tissues in cynomolgus monkeys following repeat-dose administration of a PEGylated protein.
    Fletcher AM, Tellier P, Douville J, Mansell P, Graziano MJ, Mangipudy RS, Brodie TA, Achanzar WE.
    Toxicol Lett; 2019 Dec 15; 317():120-129. PubMed ID: 31580884
    [Abstract] [Full Text] [Related]

  • 12. The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency.
    Liang Y, Zhang C, Wei H, Du H, Zhang G, Yang Y, Zhang H, Gong H, Li P, Song F, Xu Z, He R, Zhou W, Zheng H, Sun L, Luo X.
    Front Endocrinol (Lausanne); 2022 Dec 15; 13():922304. PubMed ID: 36034448
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long-acting PEGylated growth hormone in children with idiopathic short stature: time to reconsider our diagnostic and treatment policy?
    Wit JM, Joustra SD.
    Eur J Endocrinol; 2023 Jan 10; 188(1):. PubMed ID: 36651155
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS AND PATIENTS TRANSITIONING FROM PEDIATRIC TO ADULT CARE.
    Yuen KCJ, Biller BMK, Radovick S, Carmichael JD, Jasim S, Pantalone KM, Hoffman AR.
    Endocr Pract; 2019 Nov 10; 25(11):1191-1232. PubMed ID: 31760824
    [Abstract] [Full Text] [Related]

  • 17. Safety and effectiveness of Omnitrope® (somatropin) in PATRO Children: a multi-center, post-marketing surveillance study comparison of US and international cohort data.
    Backeljauw P, Kanumakala S, Loche S, Schwab KO, Miller BS, Levy R, McCormick K, Zouater H, Zabransky M, Campbell K.
    Eur J Pediatr; 2022 Jun 10; 181(6):2367-2378. PubMed ID: 35275291
    [Abstract] [Full Text] [Related]

  • 18. Safety and Effectiveness of Omnitrope®, a Biosimilar Recombinant Human Growth Hormone: More Than 10 Years' Experience from the PATRO Children Study.
    Pfäffle R, Bidlingmaier M, Kreitschmann-Andermahr I, Land C, Partsch CJ, Schwab KO, Sommer H, Backeljauw P, Kanumakala S, Loche S, Zouater H, Strasburger CJ.
    Horm Res Paediatr; 2020 Jun 10; 93(3):154-163. PubMed ID: 32814319
    [Abstract] [Full Text] [Related]

  • 19. Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: A systematic review and meta-analysis.
    Mameli C, Orso M, Calcaterra V, Wasniewska MG, Aversa T, Granato S, Bruschini P, Guadagni L, d'Angela D, Spandonaro F, Polistena B, Zuccotti G.
    Pharmacol Res; 2023 Jul 10; 193():106805. PubMed ID: 37236413
    [Abstract] [Full Text] [Related]

  • 20. Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk.
    Boguszewski CL.
    Best Pract Res Clin Endocrinol Metab; 2023 Dec 10; 37(6):101817. PubMed ID: 37643936
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.